Oncolytics Biotech Inc. has been granted its 30th US Patent, No. 7,452,723, entitled "Methods for Preventing Reovirus Recognition for the treatment of Cellular Proliferative Disorders." The allowed claims relate to kits comprised of reovirus and an immune suppressive agent that are designed to prevent reovirus recognition by the immune system.
"This US patent covers assemblies which can be used to potentially improve therapeutic benefit to patients, and broadens our coverage in the area of combination treatment," said Mary Ann Dillahunty, vice president of Intellectual Property for Oncolytics.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.